Stock comparison
LeMaitre Vascular
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 66C | LMAT |
| Benjamin Graham | 89A | 84A | LMAT |
| Philip Fisher | 81C | 65C | LMAT |
| Peter Lynch | 67B | 60C | LMAT |
| Joel Greenblatt | 56D | 40D | LMAT |
| Charlie Munger | 68D | 68D | Tie |
| Terry Smith | 69D | 58D | LMAT |
Side-by-side metrics
| Metric | LMAT | RPRX |
|---|---|---|
| Market cap | $2.23B | $23.44B |
| P/E (TTM) | 37.1x | 27.6x |
| EV/EBIT | 36.6x | 19.9x |
| ROIC (TTM) | 9.43% | 8.43% |
| Gross margin | 72.39% | 99.95% |
| Net margin | 24.35% | 33.91% |
| Revenue CAGR 5y | 12.75% | 0.96% |
| EPS CAGR 5y | 19.04% | 11.83% |
| Debt / Equity | 0.5x | 1.3x |
| Dividend yield | 0.84% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Revenue CAGR 5y12.75%vs 0.96%+93%
- Debt / Equity0.5xvs 1.3x+64%
- EPS CAGR 5y19.04%vs 11.83%+38%
- ROIC (TTM)9.43%vs 8.43%+11%
RPRX leads on
- Market cap$23.44Bvs $2.23B+90%
- Dividend yield1.72%vs 0.84%+51%
- EV/EBIT19.9xvs 36.6x+46%
- Net margin33.91%vs 24.35%+28%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.